Key insights
- Tempus AI launched the ArteraAI Prostate Test, an AI-powered prognostic tool for metastatic prostate cancer patients. This test, integrated into Tempus' platform, analyzes clinical data and biopsy images to estimate mortality risk, potentially influencing treatment decisions. While positive for Tempus AI, the overall market impact on US equities is limited.
Tempus AI, Inc. announced the clinical launch of the ArteraAI Prostate Test for patients with metastatic hormone-sensitive prostate cancer. The CLIA-certified and CAP-accredited prognostic test represents the first externally developed digital pathology algorithm available through the Tempus platform.
The AI-powered test analyzes patient clinical information and histopathology biopsy images to generate a personalized risk estimate of prostate cancer-specific mortality likelihood. The test targets approximately 25,000 patients newly diagnosed with metastatic prostate cancer in the United States annually.
Clinicians can order the ArteraAI Prostate Test as an add-on to Tempus’ solid tumor portfolio across all ordering modalities. The test combines with Tempus’ genomic-based next-generation sequencing assay results to provide clinicians with comprehensive patient assessments.
"From the start of our Tempus collaboration, our goal has been to deliver Artera’s AI-powered insights to Tempus customers in a streamlined, convenient, and impactful way," said Amanda Lowe, Chief Commercial Officer at Artera.
"By establishing this new digital pathology workflow with the ArteraAI Prostate Test, we are giving clinicians a differentiated tool to better stratify risk and tailor therapy," said Laura Elster, Chief Commercial Officer of Diagnostics at Tempus.
Artera operates as a precision medicine company using multimodal artificial intelligence for cancer care personalization. The company’s platform has been validated in multiple Phase 3 randomized trials across different cancers. Artera maintains headquarters in Los Altos, California, and operates a CLIA-certified clinical laboratory in Jacksonville, Florida.
The information is based on a company press release statement.